$BDSX
BIODESIX INC

2024 Q1 Form 10-K Financial Statement

#000095017024023513 Filed on March 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $14.82M $14.67M $49.09M
YoY Change 63.63% 52.68% 28.46%
Cost Of Revenue $3.175M $3.374M $13.01M
YoY Change 0.19% 2.06% -8.08%
Gross Profit $11.64M $11.29M $36.08M
YoY Change 97.77% 79.24% 49.96%
Gross Profit Margin 78.57% 77.0% 73.5%
Selling, General & Admin $20.56M $16.25M $67.39M
YoY Change 8.25% -2.26% 9.64%
% of Gross Profit 176.55% 143.89% 186.79%
Research & Development $2.040M $1.889M $9.988M
YoY Change -37.25% -47.01% -23.77%
% of Gross Profit 17.52% 16.73% 27.69%
Depreciation & Amortization $900.0K $977.0K $3.328M
YoY Change 200.0% 8.8% -7.48%
% of Gross Profit 7.73% 8.65% 9.22%
Operating Expenses $25.84M $18.14M $90.43M
YoY Change 1.61% -10.16% 1.84%
Operating Profit -$11.02M -$6.846M -$41.34M
YoY Change -32.69% -50.71% -18.28%
Interest Expense $2.529M -$2.329M $9.536M
YoY Change 5.77% -8.67% 18.14%
% of Operating Profit
Other Income/Expense, Net -$2.593M $60.00K -$10.80M
YoY Change 11.34% -24.05% -27.29%
Pretax Income -$13.61M -$9.139M -$52.15M
YoY Change -27.21% -55.06% -20.32%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$13.61M -$9.139M -$52.15M
YoY Change -27.21% -55.06% -20.32%
Net Earnings / Revenue -91.87% -62.31% -106.23%
Basic Earnings Per Share -$0.14 -$0.64
Diluted Earnings Per Share -$0.14 -$0.10 -$0.64
COMMON SHARES
Basic Shares Outstanding 96.94M 90.48M 82.11M
Diluted Shares Outstanding 97.17M 82.11M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $11.49M $26.28M $26.28M
YoY Change -54.54% -39.0% -39.0%
Cash & Equivalents $11.49M $26.28M $26.28M
Short-Term Investments
Other Short-Term Assets $7.095M $5.720M $5.720M
YoY Change 53.97% 10.4% 10.4%
Inventory
Prepaid Expenses
Receivables $9.893M $7.679M $7.679M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $28.48M $39.68M $39.68M
YoY Change -18.13% -25.6% -25.6%
LONG-TERM ASSETS
Property, Plant & Equipment $28.58M $27.87M $29.61M
YoY Change 118.18% 376.52% 235.7%
Goodwill $15.03M $15.03M
YoY Change 0.0% 0.0%
Intangibles $7.384M $7.911M
YoY Change -20.7% -19.25%
Long-Term Investments
YoY Change
Other Assets $6.175M $6.859M $6.859M
YoY Change -3.15% 15.8% 15.8%
Total Long-Term Assets $58.72M $59.41M $59.41M
YoY Change 27.63% 50.14% 50.14%
TOTAL ASSETS
Total Short-Term Assets $28.48M $39.68M $39.68M
Total Long-Term Assets $58.72M $59.41M $59.41M
Total Assets $87.20M $99.10M $99.10M
YoY Change 7.93% 6.66% 6.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.213M $2.929M $2.929M
YoY Change 105.57% 73.83% 73.83%
Accrued Expenses $7.898M $7.710M $5.090M
YoY Change 37.6% -6.18% -31.64%
Deferred Revenue $300.0K $300.0K
YoY Change -72.73% -70.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $45.00K $51.00K $51.00K
YoY Change -10.0% 4.08% 4.08%
Total Short-Term Liabilities $31.23M $33.42M $33.42M
YoY Change 41.33% 46.31% 46.31%
LONG-TERM LIABILITIES
Long-Term Debt $35.51M $35.23M $35.23M
YoY Change 41.57% 40.88% 40.88%
Other Long-Term Liabilities $615.0K $712.0K $25.88M
YoY Change -5.09% 27.6% 5.8%
Total Long-Term Liabilities $61.47M $61.10M $61.10M
YoY Change 13.53% 23.53% 23.53%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.23M $33.42M $33.42M
Total Long-Term Liabilities $61.47M $61.10M $61.10M
Total Liabilities $92.70M $94.52M $94.52M
YoY Change 21.59% 30.73% 30.73%
SHAREHOLDERS EQUITY
Retained Earnings -$433.2M -$419.6M
YoY Change 12.19% 14.19%
Common Stock $97.00K $96.00K
YoY Change 24.36% 23.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.502M $4.580M $4.580M
YoY Change
Total Liabilities & Shareholders Equity $87.20M $99.10M $99.10M
YoY Change 7.93% 6.66% 6.66%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$13.61M -$9.139M -$52.15M
YoY Change -27.21% -55.06% -20.32%
Depreciation, Depletion And Amortization $900.0K $977.0K $3.328M
YoY Change 200.0% 8.8% -7.48%
Cash From Operating Activities -$15.31M -$12.28M -$22.87M
YoY Change 99.21% 2.8% -49.15%
INVESTING ACTIVITIES
Capital Expenditures $234.0K $3.001M $22.92M
YoY Change -96.95% 51.03% 594.94%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$273.0K -$3.001M -$23.06M
YoY Change -96.46% 51.03% 552.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $28.13M
YoY Change -52.76%
Debt Paid & Issued, Net $13.00K $49.00K
YoY Change 8.33% -99.83%
Cash From Financing Activities 791.0K 21.73M 29.13M
YoY Change -132.67% -48.08% -50.53%
NET CHANGE
Cash From Operating Activities -15.31M -12.28M -22.87M
Cash From Investing Activities -273.0K -3.001M -23.06M
Cash From Financing Activities 791.0K 21.73M 29.13M
Net Change In Cash -14.79M 6.444M -16.80M
YoY Change -16.95% -76.91% -261.94%
FREE CASH FLOW
Cash From Operating Activities -$15.31M -$12.28M -$22.87M
Capital Expenditures $234.0K $3.001M $22.92M
Free Cash Flow -$15.55M -$15.28M -$45.79M
YoY Change 1.19% 9.68% -5.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001439725
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsCurrent
CY2022Q4 us-gaap Restricted Cash Current Asset Statement Of Financial Position Extensible List
RestrictedCashCurrentAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsCurrent
CY2023 bdsx Lease Expiration Month Year
LeaseExpirationMonthYear
2023-01
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-39659
CY2023 dei Entity Registrant Name
EntityRegistrantName
Biodesix, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3986492
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
919 West Dillon Rd
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Louisville
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80027
CY2023 dei City Area Code
CityAreaCode
303
CY2023 dei Local Phone Number
LocalPhoneNumber
417-0500
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
BDSX
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
Yes
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
36600000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
96942061
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
Denver, CO
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26284000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43088000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
65000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
118000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7679000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5065000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5720000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
5181000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
39683000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
53334000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27867000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5848000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7911000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9797000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1745000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2973000
CY2023Q4 us-gaap Goodwill
Goodwill
15031000
CY2022Q4 us-gaap Goodwill
Goodwill
15031000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6859000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5923000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
59413000
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
39572000
CY2023Q4 us-gaap Assets
Assets
99096000
CY2022Q4 us-gaap Assets
Assets
92906000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2929000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1685000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7710000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8218000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
324000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
962000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
252000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1543000
CY2023Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
21857000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
10341000
CY2023Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
51000
CY2022Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
49000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
293000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
41000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
33416000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22839000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
35225000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25004000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25163000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5254000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
18645000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
712000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
558000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
61100000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
49461000
CY2023Q4 us-gaap Liabilities
Liabilities
94516000
CY2022Q4 us-gaap Liabilities
Liabilities
72300000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96235883
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96235883
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
77614358
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
77614358
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
96000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
78000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
424050000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
387948000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-419566000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367420000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4580000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
20606000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
99096000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92906000
CY2023 us-gaap Revenues
Revenues
49087000
CY2022 us-gaap Revenues
Revenues
38212000
CY2023 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
13010000
CY2022 bdsx Direct Costs And Expenses
DirectCostsAndExpenses
14154000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9988000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13102000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
67387000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
61462000
CY2023 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
44000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
81000
CY2023 us-gaap Operating Expenses
OperatingExpenses
90429000
CY2022 us-gaap Operating Expenses
OperatingExpenses
88799000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-41342000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-50587000
CY2023 us-gaap Interest Expense
InterestExpense
9536000
CY2022 us-gaap Interest Expense
InterestExpense
8072000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6981000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1274000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-84000
CY2023 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
6000
CY2022 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
109000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10804000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14860000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-52146000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65447000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
82113000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82113000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42103000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42103000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
19727000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
56235000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
355000
CY2022 bdsx Stock Issued During Period Values For Deferred Offering Costs
StockIssuedDuringPeriodValuesForDeferredOfferingCosts
600000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
269000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2906000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5961000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65447000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
20606000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28003000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
643000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
91000
CY2023 bdsx Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Optionsvested In Period Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsvestedInPeriodAmount
1000
CY2023 bdsx Adjustments To First Amendment Warrants
AdjustmentsToFirstAmendmentWarrants
674000
CY2023 bdsx Adjustments To Additional Paid In Capital Reclassification Of Warrant
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrant
1335000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5373000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-52146000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4580000
CY2023 us-gaap Profit Loss
ProfitLoss
-52146000
CY2022 us-gaap Profit Loss
ProfitLoss
-65447000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3328000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3597000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2179000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2247000
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6981000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
5373000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5961000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1274000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-84000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
497000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
93000
CY2023 bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
5111000
CY2022 bdsx Accrued Interest Amortization Of Debt Issuance Costs And Other
AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
5037000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
166000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
906000
CY2023 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
44000
CY2022 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
81000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4718000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1501000
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-905000
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1113000
CY2023 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-33000
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3504000
CY2023 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
513000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-773000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-755000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1213000
CY2023 bdsx Increase Decrease In Contingent Consideration
IncreaseDecreaseInContingentConsideration
-2494000
CY2023 bdsx Tenant Improvement Allowances Received
TenantImprovementAllowancesReceived
18323000
CY2022 bdsx Tenant Improvement Allowances Received
TenantImprovementAllowancesReceived
2471000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-503000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-937000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22870000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44972000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
22919000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3298000
CY2023 bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
143000
CY2022 bdsx Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net
PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
236000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23062000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3534000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28126000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
59538000
CY2023 bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
643000
CY2022 bdsx Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
355000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
91000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
269000
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 bdsx Number Of Subscription Agreement For Which Final Closing To Be Delayed
NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed
1
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7520371
CY2023Q4 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
CY2023 bdsx Primary Sources Of Revenue Description
PrimarySourcesOfRevenueDescription
We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).
CY2023 us-gaap Revenues
Revenues
49087000
CY2022 us-gaap Revenues
Revenues
38212000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1000000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1300000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
300000
CY2023 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
8581000
CY2022 us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
10822000
CY2023 bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
10000000
CY2022 bdsx Proceeds From Issuance Of Term Loan And Notes Payable
ProceedsFromIssuanceOfTermLoanAndNotesPayable
45102000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
49000
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
28604000
CY2023 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
833000
CY2022 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
3725000
CY2022 bdsx Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
129000
CY2023 bdsx Payment Of Equity Financing Costs
PaymentOfEquityFinancingCosts
80000
CY2022 bdsx Payment Of Equity Financing Costs
PaymentOfEquityFinancingCosts
3069000
CY2023 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-188000
CY2022 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-33000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29129000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58882000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-16803000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10376000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43174000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32798000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26371000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43174000
CY2022 bdsx Common Stock Issued For Deferred Offering Costs
CommonStockIssuedForDeferredOfferingCosts
600000
CY2022 bdsx Deferred Offering Costs Amortized Against Additional Paid In Capital
DeferredOfferingCostsAmortizedAgainstAdditionalPaidInCapital
75000
CY2023 bdsx Debt Issuance Costs Included In Accounts Payable And Other Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
18000
CY2022 bdsx Debt Issuance Costs Included In Accounts Payable And Other Accrued Liabilities
DebtIssuanceCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
631000
CY2023 bdsx Equity Financing Costs Included In Accounts Payable And Other Accrued Liabilities
EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
43000
CY2022 bdsx Equity Financing Costs Included In Accounts Payable And Other Accrued Liabilities
EquityFinancingCostsIncludedInAccountsPayableAndOtherAccruedLiabilities
160000
CY2023 bdsx Issuance Of Perceptive Warrants
IssuanceOfPerceptiveWarrants
674000
CY2022 bdsx Issuance Of Perceptive Warrants
IssuanceOfPerceptiveWarrants
3051000
CY2022 bdsx Operating Lease Right Of Use Assets Obtained In Exchange For Lease Liabilities At Adoption Of Asc842
OperatingLeaseRightOfUseAssetsObtainedInExchangeForLeaseLiabilitiesAtAdoptionOfAsc842
1269000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
797000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3936000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
773000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
123000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
3994000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1009000
CY2023 bdsx Reclassification Of Warrant Liability To Additional Paid In Capital
ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital
1335000
CY2023 bdsx Purchases Of Property Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyEquipmentIncludedInAccountsPayableAndAccruedLiabilities
793000
CY2023 bdsx Number Of Sars Co V2 Test
NumberOfSARSCoV2Test
3
CY2023 bdsx Number Of Cancer Test
NumberOfCancerTest
5
CY2023 bdsx Number Of Commercial Blood Based Test
NumberOfCommercialBloodBasedTest
2
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Substantially all of the Company’s cash and cash equivalents are deposited with one major financial institution in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institution with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Several of the components for certain of the Company's sample collection kits, test reagents, and test systems are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, the Company could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2023 and 2022, see Note 11 — </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Accounts Receivable Credit Concentration</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
100000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
200000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
900000
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023 us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
For lease classification determination, Management continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset.
CY2023 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
For tax positions meeting the more likely than not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority.
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
33479000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12866000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5612000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7018000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27867000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5848000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18991000
CY2023Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
11080000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7911000
CY2022Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
18894000
CY2022Q4 bdsx Intangible Assets Accumulated Amortization Excluding Goodwill
IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
9097000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9797000
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1983000
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1975000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1978000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1972000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1959000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1007000
CY2023Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
59000
CY2023Q4 bdsx Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter
FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter
820000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7795000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3855000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4671000
CY2023Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
983000
CY2022Q4 bdsx Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
1232000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2872000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2315000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7710000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8218000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4802000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
5074000
CY2023Q4 us-gaap Notes Payable
NotesPayable
35276000
CY2022Q4 us-gaap Notes Payable
NotesPayable
25053000
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
51000
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
49000
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
35225000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
25004000
CY2023Q3 bdsx Number Of Subscription Agreement For Which Final Closing To Be Delayed
NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed
1
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7520371
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
50000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
21000
CY2023Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7000
CY2023Q4 bdsx Longt Erm Debt Maturities Repayments Of Principal In Year Four And Thereafter
LongtErmDebtMaturitiesRepaymentsOfPrincipalInYearFourAndThereafter
40000000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
40078000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
4300000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
2600000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10Y10M24D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.114
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2406000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4032000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4144000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4063000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
4151000
CY2023Q4 bdsx Lessee Operating Lease Liability To Be Paid Year Six And Thereafter
LesseeOperatingLeaseLiabilityToBePaidYearSixAndThereafter
28113000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
46909000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
21494000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
25415000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holder of each share of common stock is entitled to one vote per share.
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 bdsx Number Of Subscription Agreement For Which Final Closing To Be Delayed
NumberOfSubscriptionAgreementForWhichFinalClosingToBeDelayed
1
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7520371
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.97
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
123000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.74
CY2023 bdsx Stock Issued During Period Shares Stock Options Cancelled Under The Option Exchange
StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange
-589000
CY2023 bdsx Share Based Compensation Arrangements By Share Based Payment Award Option Cancelled Under The Option Exchange Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice
20.43
CY2023Q4 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2028-02-23
CY2023 bdsx Primary Sources Of Revenue Description
PrimarySourcesOfRevenueDescription
We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. We also recognize revenue from other services, including amounts derived from licensing our technologies (Biopharma Services and other).
CY2023 us-gaap Revenues
Revenues
49087000
CY2022 us-gaap Revenues
Revenues
38212000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1000000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1300000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
300000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5373000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5961000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.4
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1489000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
454000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.83
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
365000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5373000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5961000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2541000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.4
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1489000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
454000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.83
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
365000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.97
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
123000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.74
CY2023 bdsx Stock Issued During Period Shares Stock Options Cancelled Under The Option Exchange
StockIssuedDuringPeriodSharesStockOptionsCancelledUnderTheOptionExchange
-589000
CY2023 bdsx Share Based Compensation Arrangements By Share Based Payment Award Option Cancelled Under The Option Exchange Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionCancelledUnderTheOptionExchangeWeightedAverageExercisePrice
20.43
CY2023 bdsx Stock Issued During Period Shares Stock Options Granted Under The Option Exchange
StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange
123000
CY2023 bdsx Share Based Compensation Arrangements By Share Based Payment Award Option Granted Under The Option Exchange Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice
1.2
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2041000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.36
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
964000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1298000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.04
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
748000
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M20D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M24D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.801
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0132
CY2023 bdsx Stock Issued During Period Shares Stock Options Granted Under The Option Exchange
StockIssuedDuringPeriodSharesStockOptionsGrantedUnderTheOptionExchange
123000
CY2023 bdsx Share Based Compensation Arrangements By Share Based Payment Award Option Granted Under The Option Exchange Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionGrantedUnderTheOptionExchangeWeightedAverageExercisePrice
1.2
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2041000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.36
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
964000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1298000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.04
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
748000
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M20D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M24D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.801
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.726
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0398
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0132
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-52146000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65447000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82113000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-52146000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-65447000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
82113000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42103000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11482000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9461000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42103000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11482000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9461000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.05
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.01
CY2023 bdsx Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.03
CY2022 bdsx Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.04
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.20
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.23
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
72722000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
70822000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4149000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3807000
CY2023Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
5120000
CY2022Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
3036000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
234000
CY2023Q4 bdsx Deferred Tax Assets Capitalized Research Costs
DeferredTaxAssetsCapitalizedResearchCosts
4281000
CY2022Q4 bdsx Deferred Tax Assets Capitalized Research Costs
DeferredTaxAssetsCapitalizedResearchCosts
2874000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1685000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1619000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.01
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.01
CY2023 bdsx Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.03
CY2022 bdsx Effective Income Tax Rate Reconciliation Permanent Items
EffectiveIncomeTaxRateReconciliationPermanentItems
0.04
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.20
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.23
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4149000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3807000
CY2023Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
5120000
CY2022Q4 us-gaap Deferred Tax Asset Interest Carryforward
DeferredTaxAssetInterestCarryforward
3036000
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
234000
CY2023Q4 bdsx Deferred Tax Assets Capitalized Research Costs
DeferredTaxAssetsCapitalizedResearchCosts
4281000
CY2022Q4 bdsx Deferred Tax Assets Capitalized Research Costs
DeferredTaxAssetsCapitalizedResearchCosts
2874000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1685000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1619000
CY2023Q4 bdsx Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
6398000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
667000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1932000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95022000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
84324000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
93023000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
82552000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1999000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1772000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
4000
CY2023Q4 bdsx Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
-692000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1303000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1772000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1999000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1772000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
310400000
CY2023Q4 bdsx Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration
DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration
5200000
CY2023 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
expire beginning in 2026
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Explanation Of Change
ValuationAllowanceDeferredTaxAssetExplanationOfChange
Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.
CY2023 bdsx Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets
PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets
1
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10500000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15100000
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2023Q4 bdsx Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
6398000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
667000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
1932000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
95022000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
84324000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
93023000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
82552000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1999000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1772000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
4000
CY2023Q4 bdsx Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
-692000
CY2023Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1303000
CY2022Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1772000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1999000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1772000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
310400000
CY2023Q4 bdsx Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration
DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration
5200000
CY2023 us-gaap Tax Credit Carryforward Description
TaxCreditCarryforwardDescription
expire beginning in 2026
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Explanation Of Change
ValuationAllowanceDeferredTaxAssetExplanationOfChange
Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.
CY2023 bdsx Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets
PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets
1
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
10500000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15100000
CY2022Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2023Q4 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Accrued
UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
952000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
843000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
57000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
109000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
28000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1037000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
952000
CY2023 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
952000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
843000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
57000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
109000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
28000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1037000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
952000
CY2023 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
federal and state returns for all years will remain open to examination by federal and state tax authorities for three and four years, respectively, from the date of utilization of any net operating loss carryforwards.

Files In Submission

Name View Source Status
0000950170-24-023513-index-headers.html Edgar Link pending
0000950170-24-023513-index.html Edgar Link pending
0000950170-24-023513.txt Edgar Link pending
0000950170-24-023513-xbrl.zip Edgar Link pending
bdsx-20231231.htm Edgar Link pending
bdsx-20231231.xsd Edgar Link pending
bdsx-ex10_34.htm Edgar Link pending
bdsx-ex10_35.htm Edgar Link pending
bdsx-ex23_1.htm Edgar Link pending
bdsx-ex31_1.htm Edgar Link pending
bdsx-ex31_2.htm Edgar Link pending
bdsx-ex32_1.htm Edgar Link pending
bdsx-ex32_2.htm Edgar Link pending
bdsx-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img35377828_0.jpg Edgar Link pending
img35377828_1.jpg Edgar Link pending
img35377828_2.jpg Edgar Link pending
img35377828_3.jpg Edgar Link pending
img35377828_4.jpg Edgar Link pending
img35377828_5.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
bdsx-20231231_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable